Tumor antigens are initially recognized and processed by antigen-presenting cells (APCs), such as dendritic cells, and subsequently presented on MHC class I and MHC class II molecules to CD8+ T cells and CD4+ T cells, respectively, collectively driving a robust antitumor immune response. This evidence concerns the gene HLA-C and neoplasm.